The balance between production and degradation of type I collagen plays a critical role in the development and maintenance of organ and tissue integrity. It also represents the most crucial element governing the process of tissue repair. The synthesis of type I collagen gene is highly regulated by different cytokines at transcriptional level. Especially, TGF-b, a key player in the physiopathology of tissue repair, enhances type I collagen gene expression. In contrast, TNF-a whose matrix-remodeling function is opposite to that of TGF-b, reduces type I collagen gene expression. This review focuses on transcriptional regulation of type I collagen by TGF-b and TNF-a, and on the molecular mechanisms that control the antagonistic activity of TNF-a against TGF-b-driven type I collagen gene expression;
Introduction
Fibrosis is a complex tissue disease whose predominant characteristic is the excessive deposition of extracellular matrix (ECM) components, especially collagens the major fibrous proteins in ECM [1] . Collagen deposition can take place in various internal organs, including lungs liver, kidney and skin. In most cases, fibrosis is a reactive process involving different pathophysiological events such as the attraction of blood-borne cells (e.g., leukocytes, platelets, activated lymphocytes), the alteration of microvascular cells (interrupting nonthrombogenic, permeability regulating, and cell-adhesive functions of the microcirculation), and the activation of resident mesenchymal cells (fibroblasts, endothelial cells, pericytes) leading to excessive collagen deposition. Thus, the net accumulation of collagen in tissue fibrosis is a result of an imbalance between the factors leading to enhanced production and deposition, or impaired degradation and removal of collagen. Contributing to the metabolic modulation are cytokines and growth factors, a group of diverse molecules derived from blood cells, such as platelets, or elaborated locally by mesenchymal and epithelial cells [2] .
To date about 20 types of collagens have been identified. The molecular nature and functions of several collagens have been characterized [3] . Type I collagen, the major component of ECM is composed of glycine-and proline rich two-a1(I) and one-a2(I) chains which are the products of two genes, COL1A1 and COL1A2. The pro-a1(I) and pro-a2(I) polypeptide chains are synthesized by fibroblasts, osteoblasts, or odontoblasts and enter into endoplasmic reticulum where specific proline and lysine residues are hydroxylated to form hydroxyproline and hydroxylysine, respectively, which help the pro-a chains to combine with other chains by hydrogen bonds and form the triple helix procollagen structure. Procollagens are secreted by the fibroblasts through the Golgi apparatus in the extracellular space where the N-terminal and C-terminal propeptides are cleaved by specific proteases. The mature processed collagen molecules aggregates to form larger collagen fibrils and help to form the ECM with other components [4] . Therefore, normal structural and functional type I collagen production and deposition in ECM to make normal physiological connective tissue needs regulation at several steps. Abnormality in any step may cause hyper-synthesis and accumulation of collagen in ECM, which in turn causes different diseases in humans such as fibrosis. Several studies have shown that the exaggerated tissue deposition of type I collagen in this type of disease is largely due to an increase in the rate of transcription of the corresponding genes [1, 2, 5] . Therefore, it is very useful to understand the molecular mechanisms that cause the upregulation of type I collagen gene expression to better understand the fibrotic disease or other collagen related diseases. To date, numerous efforts have been made to identify the factors and the signal transduction pathways that are involved in transcription of type I collagen gene expression. Identification of the regulatory elements within the promoters of this gene and of the transcription factors that bind to these elements is, therefore, crucial for understanding the mechanisms involved in the development of tissue fibrosis.
Transcriptional regulation of Type I collagen genes by TGF-b
Transforming growth factor b (TGF-b) is a key regulator of ECM assembly and remodeling. This action is exerted through two complementary pathways, one that reduces matrix degradation and the other that stimulates matrix accumulation. In simplified terms, TGF-b inhibits the synthesis of extracellular proteinases while upregulating the production of their inhibitors and that of structural ECM components. The combined action of TGF-b on the genes implicated in the formation and degradation of the ECM is mostly exerted at the transcriptional level through well-defined intracellular pathways [6] . Thefore, in the context of fibrotic diseases, it appears crucial to understand the molecular mechanisms that cause the transcriptional response of type I collagen genes to TGF-b.
The TGF-b signal transduction machinery (Figure 1)
The T G F-b s signal via serine/threonine kinase transmembrane receptors that phosphorylate cytoplasmic mediators of the Smad family [7, 8] . The ligand-specific Smad1, Smad2, Smad3 and Smad5, interact directly with, and are phosphorylated by, activated TGFb receptors type I [8, 9 10] . Smad1 and Smad5 are specific for BMPs, whereas Smad2 and Smad3 can be activated by both TGF-b and activin receptors. They all consist of two conserved Mad-homology (MH) domains that form globular structures separated by a linker region [11] . The N-terminal MH1 domain has DNA-binding activity whereas the C-terminal MH2 domain has protein-binding properties. Phosphorylation of R-Smads by type I receptors occurs principally on two serine residues within a conserved -SS(M/V)S-motif at their Cterminus [9, 10] . Receptor-activated Smads are kept in the cytoplasm in the basal state bound to the protein SARA (Smad anchor for receptor activation) [12] . Upon phosphorylation at their SSXS carboxy-terminal motif, they are released from SARA and form heteromeric complexes with Smad4, a common mediator for all Smad pathways. The resulting Smad heterocomplexes are then translocated into the nucleus by a mechanism involving the cytoplasmic protein importin [13, 14] , where they activate target genes, binding DNA either directly or in association with other transcription factors [9, 10] . Members of the third group of Smads, the inhibitory Smads Smad6 and Smad7, prevent phosphorylation and/or nuclear translocation of receptor-associated Smads, and recruit E3-type ubiquitin ligases to the receptors complexes, ultimately leading to their degradation [15, 16] . Following target gene transcription, Smad complexes are released from the chromatin and undergo ubiquitination, followed by proteasomal degradation [17] .
Several cross-signaling mechanisms have been described that implicate Smad proteins.
For example, Smad3 interacts with the vitamin D receptor to mediate the additive effect of TGF-b on vitamin D3-induced transcription [18] . Smad3 also interacts with TFE3 and Sp1 to activate transcription from the PAI-1 and p21 cik promoters, respectively [19, 20] . Smad/AP-1 interactions have also been reported, which may lead to either additive [21, 22, 23] , or antagonistic [23, 24] activities on gene transactivation. The outcome is dependent on the structure of target promoters, as not only the presence of AP-1-and/or Smad-specific ciselements, but also their respective positions, may influence the transcriptional outcome response [22, 23] . Another possibility for Smads to interfere with other transcription factors occurs through direct interactions with transcriptional co-activators such as CBP/p300. The latter proteins modify transcription either by altering chromatin structure so that the underlying DNA sequences are exposed to the transcriptional apparatus [25] , or by directly recruiting the RNA polymerase II holoenzyme to the promoter [26] . Smad.CBP/p300
interaction is required for transcriptional activation of several TGF-b dependent promoters [27, 28, 29, 30, 31] . Several proteins including the viral oncoprotein E1A [32] , the proto- and TAB1, a novel MAP kinase kinase kinase [46, 47] and its activator, which have been shown to be important for TGF-b signaling through p38 MAP kinase. However, direct linkage between the TAB/TAK1 cascade and TGF-b receptors has not been demonstrated [48] . Downstream, components of MAP kinase-signaling pathways may also interact with the R-Smad/Smad4 complex in the nucleus, providing an additional level of transcriptional crosstalk between these pathways [49] .
Transcriptional regulation of COL1A1 by TGF-b
The human pro-COL1A1 gene is located in 17q21.31-22.05 [50] . The regulatory regions within the promoter contain several repressor and enhancer element, and several transcription factors interact with these upstream regulatory elements to control basal, cell-type-specific, and cytokine-modulated gene expression [2, 5] . fibroblasts [52] . In contrast, an AP-1 binding site located at the +598 to +604 in the first intron of a human promoter-enhancer construct has been shown to be involved in TGF-b modulation of the COL1A1 gene in Ito cells [53] . Different cell types used in these studies may account for the observed differences.
Transcriptional regulation of COL1A2 by TGF-b
Early observations demonstrated that a segment of the mouse COL1A2 promoter between -350 and -300, overlapping a nuclear factor 1 (NF1) binding-site, is needed for TGF-b stimulation in NIH 3T3 cells [54] . Regarding, the human COL1A2 promoter, original works demonstrated that a 135 bp region of the promoter within 330 bp of the transcription start site could confer responsiveness to TGF-b [55] . This rather large region was shown to contain two smaller regions, the first referred as box A, spanning nucleotides -330 to -286 and containing two distinct nuclear binding sites called 5A and 3A, the other referred to as box B, from nucleotides -271 to -255. The upstream element, box A, was shown to bind Sp1 and to confer high basal promoter activity [55] . Box B harbors both a putative AP-1 binding element and a non-canonical NF-kB binding site [55, 56] . promoter activity, and stimulated the expression of endogenous Type I collagen. The effect of p300 on COL1A2 transcription appeared to be due, in part, to its intrinsic acetyltransferase activity, as stimulation induced by a histone acetyltransferase-deficient mutant p300 was substantially reduced. Transactivation of COL1A2 by p300 involved the Smad signaling pathway, as Smad4-deficient cells failed to respond to p300, and stimulation was rescued by overexpression of Smad4 [63] .
Transcriptionnal regulation of type I collagen genes by TNF-a
Tumor necrosis alpha (TNF-a), released by activated macrophages, plays a key role in inflammatory disorders such as rheumatoid arthritis ans osteoarthritis [64] . ECM degradation is the hallmark of these conditions and an important component in morphogenesis, organogenesis, and tissue remodeling, as well as in wound healing and tissue repair. TNFa reduces ECM deposition either by inducing the production of stromal collagenases or by inhibiting the synthesis of structural components such as the type I collagen, the major structural component of connective tissue. TNF-a also counteracts TGF-b stimulation of type I collagen gene expression [65, 66, 67] . This finding reflects the functionally antagonistic nature of these cytokines and represents a useful paradigm to study the complex cellular signals that regulate ECM formation and remodeling.
The TNF-a signal transduction machinery (Figure 2)
TNF-a exerts its functions by interaction with the death domain-containing TNF- 
Transcriptional regulation of COL1A1 by TNF-a
In human dermal fibroblasts, using a series of deletion constructs or various substitution mutations of the human COL1A1 5'-flanking promoter region, Mori et al., observed that TNFa suppress promoter activity through a proximal short promoter elements containing only 107 bp [71] . EMSA experiments and functional analysis with short substitution mutations between -101 and -97 bp or between -46 and -38 bp suggest that TNF-a suppressed COL1A1 promoter activity through these elements located between -101 and -97 bp and between -46 and -38 bp of the COL1A1 promoter, and that the suppression involved interactions between DNA and yet unidentified protein [71] .
In rat hepatic stellate cells, a functional TNF-a-responsive-element (TaRE) has been identified in the -378 to -345 region of the rat COL1A1 promoter [72] . The authors demonstrated that TNF-a induces nuclear translocation and binding of transcriptional complexes containing p20C/EBPb, p35C/EBPb, and C/EBPd to this sequence of the promoter. This element co-localizes with the previously reported TGF-b-responsive element identified in the rat COL1A1 promoter [73] . The role of p38 in the down-regulation of the rat COL1A1 promoter activity by TNF-a has been recently suggested [74] .
Transcriptional regulation of COL1A2 by TNF-a
Initial observations demonstrated that a 135-bp region of the COL1A2 promoter within 330 bp of the transcription start site could confer responsiveness to TNF-a [56] . Although no specific transcription factor could be identified by Inagaki et al. [55, 56] , they postulated that unknown factors interacting with both box B and the upstream Sp1 binding sites present in box A were necessary for TNF-a responses [55, 56] . More recently, Kouba et al., identified the specific TNF-a response element (TaRE) that allows COL1A2 transcriptional inhibitory response to TNF-a in human dermal fibroblasts [75] . Specifically, the TaRE was found to reside between nucleotides -271 and -235 relative to the transcription initiation site. [80, 81] . NF-kB has been suggested to be part of the signals responsible for SMAD7 gene activation by TNF-a [82] , although it is clearly a cell-type specific mechanism [78, 83] . Alternatively, induction of c-Jun by cytokines has been shown to directly interfere with the SMAD pathway either by preventing SMAD3 binding to cognate DNA sequences or by sequestering the transcriptional coactivator p300 [23, 78, 84, 85] . In this respect, activation of JunB expression in response to SMAD signaling downstream of the TGF-b receptors was recently shown to be part of a negative autoregulatory loop attenuating SMAD-specific transcriptional responses [24] . Using a gene knockout approach, to elucidate the specific roles 
Conclusion
Excessive accumulation of collagen, especially type I collagen, is a major pathological feature in diseases characterized by tissue fibrosis. Several pharmacological agents have been tested for the effects on collagen metabolism [86] . Some of these agents, which modulated 
